What is the first-line induction therapy for Crohn’s disease?

First-Line Treatment for Crohn's Disease

The first-line treatment for Crohn's disease depends critically on disease severity and location: for mild-to-moderate ileal/right colonic disease, use oral budesonide 9 mg/day; for mild colonic disease, use sulfasalazine 4-6 g/day; for moderate-to-severe disease without high-risk features, use oral prednisone 40-60 mg/day; and for moderate-to-severe disease with high-risk features (stricturing/penetrating disease, perianal fistulas, age <40, or need for steroids at diagnosis), initiate anti-TNF biologics as first-line therapy. 1, 2

Disease Severity Assessment First

Before selecting therapy, you must assess disease severity using a combination of clinical symptoms, objective inflammatory markers (CRP, fecal calprotectin), endoscopic findings, and risk factors for poor prognosis. 1, 2 This assessment determines which treatment pathway to follow.

Treatment Algorithm by Disease Severity and Location

Mild-to-Moderate Ileal and/or Right Colonic Disease

• Oral budesonide 9 mg/day is the preferred first-line agent for inducing remission in this population. 1, 2
• Budesonide has high topical anti-inflammatory activity with low systemic bioavailability, resulting in fewer systemic side effects compared to conventional corticosteroids. 1
• Reassess clinical response between 4-8 weeks to determine if therapy modification is needed. 1, 2
• If budesonide fails, escalate to prednisone 40-60 mg/day. 1, 2
• Important caveat: Budesonide should NOT be used for maintenance therapy as it is ineffective for this purpose. 1, 2

Mild Colonic Disease (Limited to Colon)

• Sulfasalazine 4-6 g/day is the first-line option for mild Crohn's disease confined to the colon. 1, 2
• Evaluate symptomatic response between 2-4 months to determine need for therapy modification. 1, 2
• Critical distinction: Other oral 5-ASA compounds (mesalamine, mesalazine) are NOT effective for Crohn's disease and should not be used. 1, 2 The evidence shows only sulfasalazine has benefit, likely due to higher concentrations achieved in the sigmoid colon and rectum through bacterial splitting of the azo bond. 1

Moderate-to-Severe Disease (Standard Risk)

• Oral prednisone 40-60 mg/day is the initial therapy for patients without high-risk features. 1, 2
• Prednisone is twice as effective as placebo in inducing clinical remission (RR: 1.99; 95% CI: 1.51-2.64). 1
• Evaluate symptomatic response between 2-4 weeks to determine need for therapy modification. 1, 2
• Once remission is achieved, taper gradually over 8 weeks—more rapid tapering is associated with early relapse. 2
• Critical warning: Corticosteroids are completely ineffective for maintaining remission and must NEVER be used for maintenance therapy due to lack of efficacy and significant toxicity. 1, 2

Moderate-to-Severe Disease (High Risk)

Anti-TNF biologics (infliximab or adalimumab) should be initiated as first-line therapy in patients with high-risk features, which include: 1, 2, 3

• Stricturing or penetrating disease behavior at presentation
• Perianal fistulizing disease
• Age under 40 years at diagnosis
• Need for corticosteroids to control the index flare
• Extensive disease involvement

The rationale for early biologic use in high-risk patients is compelling: these features predict an aggressive disease course with higher risk of complications, hospitalization, and disability. 1, 2, 3 Delaying biologic therapy in this population leads to worse long-term outcomes. 2

• Evaluate response to anti-TNF therapy between 8-12 weeks. 2, 3
• Combination therapy with thiopurines or methotrexate should be considered alongside anti-TNF agents to reduce immunogenicity, improve pharmacokinetics, and achieve higher rates of deep remission. 2, 3 However, this must be balanced against increased infection risk, particularly in elderly patients and young males. 3
• Alternative first-line biologics include vedolizumab and ustekinumab, which can also be considered in this population. 1, 2

Severe Disease Requiring Hospitalization

• Intravenous methylprednisolone 40-60 mg/day (typically 40 mg every 8 hours) is recommended for patients with active disease severe enough to require hospitalization. 1, 2
• Evaluate symptomatic response within 1 week to determine need to modify therapy. 1, 2
• Lack of response warrants escalation to biologic therapy or surgical consultation. 2

Therapies to Avoid as First-Line

Several therapies have insufficient evidence and should NOT be used as first-line treatment: 2

• Systemic antibiotics (except for septic complications): insufficient evidence for inducing or maintaining remission 1
• Oral 5-ASA compounds other than sulfasalazine: ineffective for Crohn's disease 1, 2
• Thiopurine monotherapy: ineffective for induction of remission (RR: 1.23; 95% CI: 0.97-1.55 vs placebo) 1, 2
• Probiotics, omega-3 fatty acids, marijuana, naltrexone: no evidence of benefit 2

Maintenance Strategy After Induction

Once remission is achieved, the maintenance strategy depends on which agent induced remission:

• After biologic-induced remission: Continue the same biologic indefinitely. 2, 3
• After steroid-induced remission in selected patients: Consider thiopurines (azathioprine/mercaptopurine) or parenteral methotrexate for maintenance, particularly in patients with adverse prognostic factors. 1, 2 Evaluate at 12-16 weeks and modify if corticosteroid-free remission is not achieved. 2
• Never use corticosteroids for maintenance: This is a strong recommendation across all guidelines due to complete lack of efficacy and significant toxicity risk. 1, 2

Common Pitfalls to Avoid

• Using corticosteroids for maintenance therapy: This is ineffective and harmful—corticosteroids have no role in maintaining remission. 1, 2
• Delaying biologics in high-risk patients: Early biologic therapy prevents complications and disability in this population. 2, 3
• Prescribing 5-ASA agents other than sulfasalazine: These provide no benefit in Crohn's disease. 1, 2
• Continuing ineffective therapy beyond evaluation timeframes: Reassess at specified intervals and modify treatment promptly if response is inadequate. 1, 2
• Using thiopurines for induction: These agents are ineffective for inducing remission and should only be considered for maintenance. 1, 2